YU27195A - Oralni dozni oblik azitromicina - Google Patents
Oralni dozni oblik azitromicinaInfo
- Publication number
- YU27195A YU27195A YU27195A YU27195A YU27195A YU 27195 A YU27195 A YU 27195A YU 27195 A YU27195 A YU 27195A YU 27195 A YU27195 A YU 27195A YU 27195 A YU27195 A YU 27195A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- azithromycin
- oral dosage
- dosage form
- usp
- forms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Opisani su oralni dozni oblici azitromicina kao što su tablete sa dodatnim dezintegralom, prah za oralnu suspenziju sa anhidrovanim puferom ili jedinično dozno pakovanje sa sredstvom za dispergovanje. Svaki od oblika ima jednu ili obe od sledećih osobina: (i) rastvorljivost azitromicina od najmanje oko 90 % tokom oko 30 minuta kada se količina doznog oblika ekvivalentna 200 mg azitromicina testira prema USP testu <711>u USP-2 aparaturi za rastvaranje pod najmanje sledećim striktno povezanim uslovima: 900 ml natrijumfosfatni pufer, pH od 6,0, pri 37В°C, sa lopaticama koje se okreću pri 100 sec-1; i/ili (ii) vrednost (AUCfed)/(AUCfst) od najmanje 0,80 sa donjom 90-postotnom granicom pouzdanosti od najmanje 0,75. Prethodno uzeta hrana ne pokazuje negativne efekte na bilo koji od ovih oblika.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/235,069 US5605889A (en) | 1994-04-29 | 1994-04-29 | Method of administering azithromycin |
Publications (2)
Publication Number | Publication Date |
---|---|
YU27195A true YU27195A (sh) | 1999-03-04 |
YU49483B YU49483B (sh) | 2006-08-17 |
Family
ID=22883977
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YU27195A YU49483B (sh) | 1994-04-29 | 1995-04-28 | Oralni dozni oblik azitromicina |
Country Status (31)
Country | Link |
---|---|
US (2) | US5605889A (sh) |
EP (1) | EP0679400B1 (sh) |
JP (3) | JPH07300420A (sh) |
KR (1) | KR100354310B1 (sh) |
CN (1) | CN1088362C (sh) |
AP (1) | AP566A (sh) |
AT (1) | ATE183395T1 (sh) |
AU (1) | AU709328B2 (sh) |
CA (1) | CA2148071C (sh) |
CO (1) | CO4560547A1 (sh) |
DE (1) | DE69511451T2 (sh) |
DK (1) | DK0679400T3 (sh) |
DZ (1) | DZ1877A1 (sh) |
ES (1) | ES2136247T3 (sh) |
FI (1) | FI952060A (sh) |
GR (1) | GR3031290T3 (sh) |
HU (1) | HUT75244A (sh) |
IL (1) | IL113437A (sh) |
LV (1) | LV10918B (sh) |
MA (1) | MA23533A1 (sh) |
NO (1) | NO314386B1 (sh) |
NZ (1) | NZ548384A (sh) |
OA (1) | OA10151A (sh) |
RU (1) | RU2128998C1 (sh) |
SI (1) | SI0679400T1 (sh) |
TN (1) | TNSN95046A1 (sh) |
TW (1) | TW499311B (sh) |
UA (1) | UA34464C2 (sh) |
UY (1) | UY23935A1 (sh) |
YU (1) | YU49483B (sh) |
ZA (1) | ZA953439B (sh) |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ292360B6 (cs) † | 1994-05-06 | 2003-09-17 | Pfizer Inc. | Dávkovací forma s řízeným uvolňováním obsahující azithromycin a způsob její výroby |
ES2079327B1 (es) * | 1994-12-13 | 1996-08-01 | Lilly Sa | Formulaciones farmaceuticas de cefaclor. |
PL186386B1 (pl) * | 1995-02-08 | 2004-01-30 | Yamanouchi Europ Bv | Sposób wytwarzania granulatu zawierającego aktywny przy podawaniu drogą doustną antybiotyk beta-laktamowy oraz sposób wytwarzania szybko rozpadającejsię postaci dawkowania zawierającej aktywny przy podawaniu drogą doustną antybiotyk beta-laktamowy |
US6383810B2 (en) * | 1997-02-14 | 2002-05-07 | Invitrogen Corporation | Dry powder cells and cell culture reagents and methods of production thereof |
US20060003447A1 (en) * | 2003-12-30 | 2006-01-05 | Richard Fike | Dry powder cells and cell culture reagents and methods of production thereof |
US20030212123A1 (en) * | 1997-05-05 | 2003-11-13 | Pfizer Inc. | COX-2 selective carprofen for treating pain and inflammation in dogs |
US6146655A (en) * | 1997-08-29 | 2000-11-14 | Softy-Flex Inc. | Flexible intra-oral bandage and drug delivery system |
US6129932A (en) * | 1997-09-05 | 2000-10-10 | Merck & Co., Inc. | Compositions for inhibiting platelet aggregation |
US6861411B1 (en) | 1997-12-02 | 2005-03-01 | Pfizer, Inc. | Method of treating eye infections with azithromycin |
US5955107A (en) * | 1997-12-12 | 1999-09-21 | Fmc Corporation | Pharmaceutical suspension tablet compositions |
US5914128A (en) * | 1997-12-22 | 1999-06-22 | Schering Corporation | Orally administrable solid dosage form |
US5916594A (en) * | 1997-12-22 | 1999-06-29 | Schering Corporation | Process of making solid ribavirin dosage forms |
CA2323849C (en) * | 1997-12-22 | 2002-06-11 | Schering Corporation | Orally administrable solid ribavirin dosage forms and process for making them |
US6239112B1 (en) * | 1998-07-09 | 2001-05-29 | Merial, Inc. | Water miscible macrolide solutions |
FR2793690B1 (fr) * | 1999-03-30 | 2003-01-03 | Cll Pharma | Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique |
BR0009437A (pt) * | 1999-03-31 | 2002-01-15 | Janssen Pharmaceutica Nv | Amido pré-gelatinizado em uma formulação de liberação controlada |
US6239113B1 (en) | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
US7056893B2 (en) * | 1999-03-31 | 2006-06-06 | Insite Vision, Inc. | Topical treatment for prevention of ocular infections |
IL141438A0 (en) * | 2000-02-23 | 2002-03-10 | Pfizer Prod Inc | Method of increasing the bioavailability and tissue penetration of azithromycin |
US20030219405A1 (en) * | 2002-01-16 | 2003-11-27 | Yoshihiro Sokawa | Oral administration of interferon-tau |
DE60026718T2 (de) * | 2000-07-25 | 2006-11-16 | Laboratorio Silanes, S.A. De C.V. | Einstufiges verfahren zur herstellung von 7,16-deoxy-2-aza-10-o-cladinosil-12-o-desosaminil-4,5-dihydroxi-6-ethyl-3,5,9,11,13,15-hexamethylbicycle(11.2.11)hexadeca-1(2)-en-8-ona undeine neue form von 9-desoxo-9a-methyl-9a-aza-9a-homoerythromycin a |
EP1313749B1 (en) * | 2000-08-23 | 2005-10-12 | Wockhardt Limited | Process for preparation of anhydrous azithromycin |
WO2002036735A2 (en) * | 2000-11-06 | 2002-05-10 | Invitrogen Corporation | Dry powder cells and cell culture reagents and methods of production thereof |
US7119076B2 (en) * | 2000-11-15 | 2006-10-10 | Masao Sugamata | Preventives or remedies for endometriosis or uterine myoma |
HRP20010301A2 (en) * | 2001-04-27 | 2001-12-31 | Pliva D D | New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases |
SI1390377T1 (sl) | 2001-05-22 | 2006-06-30 | Pfizer Prod Inc | Nova kristalna oblika azitromicina |
EA007618B1 (ru) * | 2001-05-22 | 2006-12-29 | Пфайзер Продактс Инк. | Кристаллический полуторогидрат азитромицина, содержащая его фармацевтическая композиция и способ лечения на его основе |
CZ2004232A3 (cs) * | 2001-08-21 | 2005-10-12 | Pfizer Products Inc. | Jednorázová dávka azithromycinu |
GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
AU2006218279B2 (en) * | 2001-09-28 | 2009-12-10 | Novartis Ag | Pharmaceutical compositions comprising colloidal silicon dioxide |
EP1541134A3 (en) * | 2001-10-18 | 2007-06-06 | Teva Pharmaceutical Industries Limited | Stabilized azithromycin compositions |
US20080149521A9 (en) * | 2001-10-18 | 2008-06-26 | Michael Pesachovich | Methods of stabilizing azithromycin |
US6764997B2 (en) * | 2001-10-18 | 2004-07-20 | Teva Pharmaceutical Industries Ltd. | Stabilized azithromycin compositions |
CN1668282A (zh) * | 2001-12-21 | 2005-09-14 | 辉瑞产品公司 | 可直接压制的阿齐霉素配方 |
CN1606433A (zh) * | 2001-12-21 | 2005-04-13 | 辉瑞产品公司 | 阿齐霉素湿法制粒法 |
WO2003063838A1 (en) * | 2002-02-01 | 2003-08-07 | Pfizer Products Inc. | Dry granulated formulations of azithromycin |
WO2003074029A1 (en) * | 2002-03-07 | 2003-09-12 | Vectura Limited | Fast melt multiparticulate formulations for oral delivery |
US7101576B2 (en) * | 2002-04-12 | 2006-09-05 | Elan Pharma International Limited | Nanoparticulate megestrol formulations |
US20100226989A1 (en) * | 2002-04-12 | 2010-09-09 | Elan Pharma International, Limited | Nanoparticulate megestrol formulations |
US9101540B2 (en) | 2002-04-12 | 2015-08-11 | Alkermes Pharma Ireland Limited | Nanoparticulate megestrol formulations |
US20040105889A1 (en) * | 2002-12-03 | 2004-06-03 | Elan Pharma International Limited | Low viscosity liquid dosage forms |
GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
BG748Y1 (bg) * | 2002-07-02 | 2005-06-30 | "BALKANFARMA-RAZGRAD" AD A{ô{òM{}ö{ }{GC}{D A{DAAAAAAAAAAAAAAAAAAAAAAAAAA | ЛЕКАРСТВЕНАБФОРМАБББББББББББББББББББББББББББББББББФЕДЙГБФЕХгЦдв@ЖЦЩФ@@@@@@@@@@@ |
WO2004074132A1 (en) * | 2003-02-19 | 2004-09-02 | Teva Pharmaceutical Industries Ltd. | Methods of stabilizing azithromycin during storage by packaging in a gas impermeable container |
US8507000B2 (en) * | 2003-05-06 | 2013-08-13 | Nostrum Pharmaceuticals, Inc. | Controlled release formulation of erythromycin derivatives |
US20050013835A1 (en) * | 2003-07-15 | 2005-01-20 | Pfizer Inc. | Stable non-dihydrate azithromycin oral suspensions |
DE602004019288D1 (de) * | 2003-07-24 | 2009-03-19 | Pliva Hrvatska D O O | Schnellösliches azithromycin in einzeldosisform |
TWI366442B (en) * | 2003-07-30 | 2012-06-21 | Novartis Ag | Palatable ductile chewable veterinary composition |
WO2005021056A1 (en) * | 2003-08-21 | 2005-03-10 | Cns, Inc. | Effervescent delivery system |
WO2005053639A2 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Controlled release multiparticulates formed with dissolution enhancers |
WO2005053652A1 (en) | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride |
US6984403B2 (en) * | 2003-12-04 | 2006-01-10 | Pfizer Inc. | Azithromycin dosage forms with reduced side effects |
CN1889931A (zh) * | 2003-12-04 | 2007-01-03 | 辉瑞产品公司 | 利用挤压器制备优选含泊洛沙姆和甘油酯的多重粒子阿奇霉素组合物的喷雾-冻凝方法 |
BRPI0417348A (pt) * | 2003-12-04 | 2007-03-13 | Pfizer Prod Inc | processo de gelatinização por spray com utilização de uma extrusora para preparação de composições de droga cristalina multiparticulada contendo preferencialmente um poloxámero e um glicerìdeo |
UA78793C2 (en) * | 2003-12-04 | 2007-04-25 | Pfizer Prod Inc | Oral dosage form of azitromycin with decreased side effects |
MXPA06005913A (es) * | 2003-12-04 | 2006-06-27 | Pfizer Prod Inc | Formas de dosificacion de multiparticulas de azitromicina por procedimientos basados en liquidos. |
CA2547597A1 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate compositions with improved stability |
ES2308274T3 (es) * | 2003-12-04 | 2008-12-01 | Pfizer Products Inc. | Procedimiento para fabricar multiparticulados farmaceuticos. |
US20050131079A1 (en) * | 2003-12-10 | 2005-06-16 | Pujara Chetan P. | Cefdinir oral suspension |
US20050239735A1 (en) * | 2003-12-30 | 2005-10-27 | 3M Innovative Properties Company | Enhancement of immune responses |
US20060116336A1 (en) * | 2004-03-17 | 2006-06-01 | American Pharmaceutical Partners, Inc. | Lyophilized azithromycin formulation |
US7468428B2 (en) * | 2004-03-17 | 2008-12-23 | App Pharmaceuticals, Llc | Lyophilized azithromycin formulation |
JP4713104B2 (ja) * | 2004-08-04 | 2011-06-29 | ファイザー株式会社 | アジスロマイシン類を有効成分とする苦味が抑制された安定な組成物 |
US20060046970A1 (en) * | 2004-08-31 | 2006-03-02 | Insite Vision Incorporated | Topical otic compositions and methods of topical treatment of prevention of otic infections |
US20060182806A1 (en) * | 2004-11-08 | 2006-08-17 | Mintong Guo | Extended-release propranolol composition |
CA2595988A1 (en) * | 2005-01-27 | 2006-08-03 | Alembic Limited | Extended release formulation of levetiracetam |
US20060198895A1 (en) * | 2005-03-07 | 2006-09-07 | Kotliar Eleonora M | Azithromycin powder for oral suspension compositions |
EP1855693B1 (en) * | 2005-03-07 | 2009-07-29 | Teva Pharmaceutical Industries Ltd. | Azithromycin powder for oral suspension compositions |
DK1884242T3 (da) | 2005-05-26 | 2013-05-06 | Dainippon Sumitomo Pharma Co | Farmaceutisk sammensætning omfattende lurasidon |
CA2618977C (en) * | 2005-08-10 | 2014-10-21 | Shionogi & Co., Ltd. | Orally disintegratable tablet |
US20070191271A1 (en) * | 2006-02-10 | 2007-08-16 | Dow Pharmaceutical Sciences | Method for stabilizing polypeptides lacking methionine |
US8187659B2 (en) | 2006-05-02 | 2012-05-29 | Jerry Robertson Real Estate Llc | Solid medicament dosage form consumption aid |
US20080014271A1 (en) * | 2006-07-13 | 2008-01-17 | Ucb, S.A. | Novel pharmaceutical compositions comprising levetiracetam |
US8124123B2 (en) * | 2007-09-05 | 2012-02-28 | Dow Pharmaceutical Sciences, Inc. | Controlled release azithromycin solid dosages forms |
PT2554168T (pt) | 2010-03-29 | 2018-02-28 | Astellas Pharma Inc | Composição farmacêutica de libertação controlada |
WO2013088274A1 (en) | 2011-12-14 | 2013-06-20 | Wockhardt Limited | Anhydrous amorphous azithromycin composition free of azithromycin dihydrate |
AP2014007874A0 (en) | 2012-02-06 | 2014-08-31 | Merial Ltd | Parasiticidal oral veterinary compositions comprising systemetically- acting active agents, methods and uses thereof |
JP5941558B2 (ja) | 2012-02-28 | 2016-06-29 | 株式会社ソウル製薬Seoul Pharma. Co., Ltd. | シルデナフィルを有効成分として含有し、且つ、苦味の隠蔽された高含量速溶フィルム |
RU2498805C1 (ru) * | 2012-07-23 | 2013-11-20 | Открытое акционерное общество "Биосинтез" | Твердая лекарственная форма азитромицина |
CN104177457A (zh) * | 2013-05-23 | 2014-12-03 | 长春海悦药业有限公司 | 一种阿奇霉素药物原料及其制剂和用途 |
US20150132382A1 (en) * | 2013-11-11 | 2015-05-14 | Forest Laboratories Holdings Ltd. | Compositions and methods of treatment comprising fosfomycin disodium |
RU2649834C1 (ru) * | 2016-07-06 | 2018-04-04 | Фармалидер С.А. | Фармацевтическая композиция силденафила цитрата в форме суспензии для перорального применения |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI8110592A8 (en) * | 1981-03-06 | 1996-06-30 | Pliva Pharm & Chem Works | Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof |
US4382085A (en) * | 1982-03-01 | 1983-05-03 | Pfizer Inc. | 4"-Epi erythromycin A and derivatives thereof as useful antibacterial agents |
US4474768A (en) * | 1982-07-19 | 1984-10-02 | Pfizer Inc. | N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor |
RU2066324C1 (ru) | 1987-07-09 | 1996-09-10 | Пфайзер Инк. | Кристаллический дигидрат азитромицина и способ его получения |
WO1989002271A1 (en) * | 1987-09-10 | 1989-03-23 | Pfizer | Azithromycin and derivatives as antiprotozoal agents |
SI9011409A (en) * | 1990-07-18 | 1995-10-31 | Pliva Pharm & Chem Works | O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them |
EP0553353A1 (en) * | 1990-10-15 | 1993-08-04 | Taisho Pharmaceutical Co. Ltd | 2'-modified erythromycin or derivative thereof |
TW271400B (sh) | 1992-07-30 | 1996-03-01 | Pfizer | |
CA2173109A1 (en) | 1993-10-01 | 1995-04-13 | Kenneth Shyer Kornman | Use of azithromycin for the treatment of adult periodontitis and topical compositions for this use |
CZ292360B6 (cs) | 1994-05-06 | 2003-09-17 | Pfizer Inc. | Dávkovací forma s řízeným uvolňováním obsahující azithromycin a způsob její výroby |
-
1994
- 1994-04-29 US US08/235,069 patent/US5605889A/en not_active Ceased
- 1994-10-18 TW TW083109662A patent/TW499311B/zh not_active IP Right Cessation
-
1995
- 1995-03-15 UY UY23935A patent/UY23935A1/es not_active IP Right Cessation
- 1995-04-06 AP APAP/P/1995/000728A patent/AP566A/en active
- 1995-04-20 DE DE69511451T patent/DE69511451T2/de not_active Expired - Fee Related
- 1995-04-20 ES ES95302628T patent/ES2136247T3/es not_active Expired - Lifetime
- 1995-04-20 SI SI9530303T patent/SI0679400T1/xx not_active IP Right Cessation
- 1995-04-20 EP EP95302628A patent/EP0679400B1/en not_active Expired - Lifetime
- 1995-04-20 AT AT95302628T patent/ATE183395T1/de not_active IP Right Cessation
- 1995-04-20 JP JP7117628A patent/JPH07300420A/ja active Pending
- 1995-04-20 DK DK95302628T patent/DK0679400T3/da active
- 1995-04-20 UA UA95048352A patent/UA34464C2/uk unknown
- 1995-04-20 IL IL11343795A patent/IL113437A/en active IP Right Grant
- 1995-04-25 CN CN95104770A patent/CN1088362C/zh not_active Expired - Fee Related
- 1995-04-26 MA MA23865A patent/MA23533A1/fr unknown
- 1995-04-26 TN TNTNSN95046A patent/TNSN95046A1/fr unknown
- 1995-04-26 DZ DZ950046A patent/DZ1877A1/fr active
- 1995-04-27 CA CA002148071A patent/CA2148071C/en not_active Expired - Lifetime
- 1995-04-27 HU HU9501206A patent/HUT75244A/hu unknown
- 1995-04-28 NZ NZ548384A patent/NZ548384A/en not_active IP Right Cessation
- 1995-04-28 KR KR1019950010253A patent/KR100354310B1/ko not_active IP Right Cessation
- 1995-04-28 ZA ZA953439A patent/ZA953439B/xx unknown
- 1995-04-28 FI FI952060A patent/FI952060A/fi not_active Application Discontinuation
- 1995-04-28 AU AU17711/95A patent/AU709328B2/en not_active Ceased
- 1995-04-28 NO NO19951630A patent/NO314386B1/no unknown
- 1995-04-28 LV LVP-95-115A patent/LV10918B/en unknown
- 1995-04-28 YU YU27195A patent/YU49483B/sh unknown
- 1995-04-28 CO CO95017782A patent/CO4560547A1/es unknown
- 1995-04-28 OA OA60654A patent/OA10151A/en unknown
- 1995-04-28 RU RU95106639A patent/RU2128998C1/ru not_active IP Right Cessation
-
1999
- 1999-09-22 GR GR990402388T patent/GR3031290T3/el unknown
-
2004
- 2004-04-23 JP JP2004128641A patent/JP2005015466A/ja active Pending
-
2005
- 2005-01-20 US US11/041,194 patent/USRE39149E1/en not_active Expired - Lifetime
-
2008
- 2008-05-28 JP JP2008139689A patent/JP2008231120A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
YU27195A (sh) | Oralni dozni oblik azitromicina | |
HUP9902121A2 (hu) | Gonadotropin-leadó hormon antagonista hatású indolszármazékok és ezeket a vegyületeket tartalmazó gyógyszerkészítmények | |
PT99593B (pt) | Processo de preparacao de uma composicao portadora liquida a base de eter de celulose e de composicoes farmaceuticas que as contem | |
YU35893A (sh) | Formulacije oksidona sa kontrolisanim otpuštanjem i njihova upotreba | |
MEP30008A (en) | Sustained release preparations | |
IT1248702B (it) | Agente antitussivo e mucoregolatore,sua preparazione e composizioni farmaceutiche | |
FI945081A (fi) | Stabiili hydratoitu kefalosporiinikuivajauhe oraaliseen suspensioformulaatioon | |
BR9912980A (pt) | Composição farmacêutica administrável oralmente, utilização de compostos, tablete de mascar e processos para evitar a sìndrome de vazamento anal de óleo | |
IT1282353B1 (it) | Composizione farmaceutica, in particolare liquida, per sommanistrazione orale di ondansetron e metodi per la sua produzione | |
MEP10808A (en) | Solid drug for oral use | |
KR920003971A (ko) | 점안액 조성물 | |
ATE275945T1 (de) | Oral anzuwendende arzneizubereitung | |
TR199801861T2 (xx) | Farmas�tik olarak yararl� bile�imler. | |
Chun et al. | Effect of enteral glutamine on intestinal permeability and bacterial translocation after abdominal radiation injury in rats | |
SE9201249L (sv) | Antikonception vid primater av honkoen utan paaverkan av den menstruella cykeln | |
NO973646L (no) | Orale doseringsformer inneholdende et <beta>-laktam antibiotikum | |
IL102814A0 (en) | Pyrazine derivatives,their preparation and pharmaceutical compositions comprising them | |
Toskes et al. | The role of the pancreas in vitamin B 12 absorption: studies of vitamin B 12 absorption in partially pancreatectomized rats | |
ME00074B (me) | Benzotiofeni, formulacije koje ih sadrže i proizvod | |
JPS5661311A (en) | Thial amide or prolonged pharmaceutical preparation comprising its salt | |
Nouws et al. | The acetylation‐deacetylation equilibrium of sulfadimidine in ruminant calves | |
Weisberg et al. | Hydroxocobalamin. VI. Comparison of intestinal absorption in man of large doses of hydroxocobalamin and cyanocobalamin. | |
RU2154467C2 (ru) | СОСТАВ ИНГИБИТОРА 5α-РЕДУКТАЗЫ ДЛЯ ОРАЛЬНОГО ВВЕДЕНИЯ, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО ИСПОЛЬЗОВАНИЕ | |
DK0484372T3 (da) | Anvendelse af sebacinsyre og derivater deraf til fremstilling af farmaceutiske præparater til enteral og parenteral ernæring | |
JPH0597708A (ja) | 歯周病治療剤 |